Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Pivot

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 16, 2018
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival resultsX Pivot, I Bondarenko, Z Nowecki, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 28, 2001
[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]N Magné, X Pivot, P Y Marcy, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer studyX Pivot, J P Spano, M Espie, et al.
Breast Cancer Research and Treatment|December 23, 2022
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancerH Bischoff, C Bigot, F Moinard-Butot, et al.
British Journal of Cancer|December 17, 2011
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyB Royer, E Kalbacher, S Onteniente, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerE Vrdoljak, N Marschner, C Zielinski, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 1998
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II studyR J Bensadoun, M C Etienne, O Dassonville, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancerR Bell, J Brown, M Parmar, et al.
Oncoimmunology|May 4, 2018
In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trialO Adotevi, Y Godet, J Galaine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|February 16, 2018
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival resultsX Pivot, I Bondarenko, Z Nowecki, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 28, 2001
[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]N Magné, X Pivot, P Y Marcy, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer studyX Pivot, J P Spano, M Espie, et al.
Breast Cancer Research and Treatment|December 23, 2022
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancerH Bischoff, C Bigot, F Moinard-Butot, et al.
British Journal of Cancer|December 17, 2011
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyB Royer, E Kalbacher, S Onteniente, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerE Vrdoljak, N Marschner, C Zielinski, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 1998
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II studyR J Bensadoun, M C Etienne, O Dassonville, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancerR Bell, J Brown, M Parmar, et al.
Oncoimmunology|May 4, 2018
In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trialO Adotevi, Y Godet, J Galaine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
Pageof 10